Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue—
Net Income-$4.87M-$4.87MN/M vs Q3 2023 EPS Diluted-$36.21-$36.21N/M vs Q3 2023 Operating Income-$4,458,259N/M Operating Cash Flowderived-$2,517,932N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end